PLOD2 Promotes Colorectal Cancer Progression by Stabilizing USP15 to Activate the AKT/mTOR Signaling Pathway

Overview

Journal Cancer Sci

Specialty Oncology

Date 2023 May 25

PMID 37227305

Authors

Jiawen Lan

Sijing Zhang

Lin Zheng

Xiaoli Long

Jianxiong Chen

Xunhua Liu

Miao Zhou

Jun Zhou

Affiliations

Soon will be listed here.

Abstract

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) has been reported as an oncogenic gene, affecting various malignant tumors, including endometrial carcinoma, osteosarcoma, and gastric cancer. These effects are mostly due to the enhanced deposition of collagen precursors. However, more studies need to be conducted on how its lysyl hydroxylase function affects cancers like colorectal carcinoma (CRC). Our present results showed that PLOD2 expression was elevated in CRC, and its higher expression was associated with poorer survival. Overexpression of PLOD2 also facilitated CRC proliferation, invasion, and metastasis in vitro and in vivo. In addition, PLOD2 interacted with USP15 by stabilizing it in the cytoplasm and then activated the phosphorylation of AKT/mTOR, thereby promoting CRC progression. Meanwhile, minoxidil was demonstrated to downregulate the expression of PLOD2 and suppress USP15, and the phosphorylation of AKT/mTOR. Our study reveals that PLOD2 plays an oncogenic role in colorectal carcinoma, upregulating USP15 and subsequently activating the AKT/mTOR pathway.

Citing Articles

N6-methyladenosine-modification of USP15 regulates chemotherapy resistance by inhibiting LGALS3 ubiquitin-mediated degradation via AKT/mTOR signaling activation pathway in hepatocellular carcinoma.

Fang R, Jia Z, Xin Y, Zhao K, Qin W, Lu H Cell Death Discov. 2025; 11(1):3.

PMID: 39794359 PMC: 11724082. DOI: 10.1038/s41420-024-02282-y.

TDERS, an exosome RNA-derived signature predicts prognosis and immunotherapeutic response in clear cell renal cell cancer: a multicohort study.

Jiang A, Liu Y, He Z, Liu W, Yang Q, Fang Y J Natl Cancer Cent. 2024; 4(4):382-394.

PMID: 39735439 PMC: 11674438. DOI: 10.1016/j.jncc.2024.07.002.

PLOD2 exacerbates cervical squamous cell carcinoma by suppressing p53 by binding to YAP1.

Yin M, Weng Y, Qi T Mol Med Rep. 2024; 31(1).

PMID: 39513600 PMC: 11576930. DOI: 10.3892/mmr.2024.13388.

USP15 as a Potential Therapeutic Target in Cerebral Ischemia: Modulation of Ferroptosis and Cognitive Dysfunction via the Nrf2/GPX4 Axis in Mice.

Yi H, Xiao X, Lei F, Zhang F Neuromolecular Med. 2024; 26(1):44.

PMID: 39508887 DOI: 10.1007/s12017-024-08813-1.

Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer.

Frame G, Leong H, Haas R, Huang X, Wright J, Emmenegger U BJC Rep. 2024; 2(1):60.

PMID: 39184453 PMC: 11338830. DOI: 10.1038/s44276-024-00085-3.

References

van der Slot A, Zuurmond A, Bardoel A, Wijmenga C, Pruijs H, Sillence D . Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003; 278(42):40967-72. DOI: 10.1074/jbc.M307380200. View

Jurj A, Ionescu C, Berindan-Neagoe I, Braicu C . The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. J Exp Clin Cancer Res. 2022; 41(1):276. PMC: 9479349. DOI: 10.1186/s13046-022-02484-1. View

Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini M . Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets. 2020; 22(9):998-1009. DOI: 10.2174/1389450121999201117115717. View

Komander D, Clague M, Urbe S . Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009; 10(8):550-63. DOI: 10.1038/nrm2731. View

Gilkes D, Bajpai S, Chaturvedi P, Wirtz D, Semenza G . Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts. J Biol Chem. 2013; 288(15):10819-29. PMC: 3624462. DOI: 10.1074/jbc.M112.442939. View

Shen Y, Wang X, Lu J, Salfenmoser M, Wirsik N, Schleussner N . Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer. Cancer Cell. 2020; 37(6):800-817.e7. DOI: 10.1016/j.ccell.2020.05.005. View

Eichhorn P, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E . USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med. 2012; 18(3):429-35. DOI: 10.1038/nm.2619. View

Du W, Liu N, Zhang Y, Liu X, Yang Y, Chen W . PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2. Biochem Cell Biol. 2019; 98(3):386-395. DOI: 10.1139/bcb-2019-0256. View

Sawicki T, Ruszkowska M, Danielewicz A, Niedzwiedzka E, Arlukowicz T, Przybylowicz K . A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers (Basel). 2021; 13(9). PMC: 8122718. DOI: 10.3390/cancers13092025. View

10.

Siegel R, Miller K, Sauer A, Fedewa S, Butterly L, Anderson J . Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70(3):145-164. DOI: 10.3322/caac.21601. View

11.

Song Y, Zheng S, Wang J, Long H, Fang L, Wang G . Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget. 2017; 8(26):41947-41962. PMC: 5522040. DOI: 10.18632/oncotarget.16710. View

12.

Wan J, Qin J, Cao Q, Hu P, Zhong C, Tu C . Hypoxia-induced PLOD2 regulates invasion and epithelial-mesenchymal transition in endometrial carcinoma cells. Genes Genomics. 2019; 42(3):317-324. DOI: 10.1007/s13258-019-00901-y. View

13.

Cheriyamundath S, Kumar A, Gavert N, Brabletz T, Ben-Zeev A . The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression. Int J Mol Sci. 2021; 22(7). PMC: 8038063. DOI: 10.3390/ijms22073552. View

14.

Yu B, Shen B, Ba Z, Liu Z, Yuan J, Zhao W . USP15 promotes the apoptosis of degenerative nucleus pulposus cells by suppressing the PI3K/AKT signalling pathway. J Cell Mol Med. 2020; 24(23):13813-13823. PMC: 7754067. DOI: 10.1111/jcmm.15971. View

15.

Liu W, Huang K, Lu M, Huang H, Chen C, Cheng Y . TGF-β upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability. Oncogene. 2016; 36(19):2715-2723. PMC: 5442427. DOI: 10.1038/onc.2016.424. View

16.

Tseng W, Leong X, Engleman E . Orthotopic mouse model of colorectal cancer. J Vis Exp. 2008; (10):484. PMC: 2557075. DOI: 10.3791/484. View

17.

Pankova D, Chen Y, Terajima M, Schliekelman M, Baird B, Fahrenholtz M . Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2015; 14(3):287-95. PMC: 4794404. DOI: 10.1158/1541-7786.MCR-15-0307. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Faesen A, Luna-Vargas M, Sixma T . The role of UBL domains in ubiquitin-specific proteases. Biochem Soc Trans. 2012; 40(3):539-45. DOI: 10.1042/BST20120004. View

20.

Provenzano P, Eliceiri K, Campbell J, Inman D, White J, Keely P . Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006; 4(1):38. PMC: 1781458. DOI: 10.1186/1741-7015-4-38. View